KVV31301
PEDV Spike glycoprotein (RBD)
Colorimetric
Plasma, Serum
Quantitative
1.56 - 100 ng/mL
0.65 ng/mL
CV<15%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Designed miniproteins potently inhibit and protect against MERS-CoV., PMID:40450691
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories., PMID:39772242
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:39644492
Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses., PMID:39488210
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification., PMID:39383863
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals., PMID:39197450
Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans., PMID:39058596
Human coronavirus HKU1 recognition of the TMPRSS2 host receptor., PMID:38964328
Spike deep mutational scanning helps predict success of SARS-CoV-2 clades., PMID:38961298
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission., PMID:38953636
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38944664
Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions., PMID:38932494
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study., PMID:38921803
Murine alveolar macrophages rapidly accumulate intranasally administered SARS-CoV-2 Spike protein leading to neutrophil recruitment and damage., PMID:38507462
Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans., PMID:38490197
Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity., PMID:38459086
Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus., PMID:37989312
Neutralization, effector function and immune imprinting of Omicron variants., PMID:37648855
Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics., PMID:36503013
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice., PMID:35988541
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern., PMID:35695453
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike., PMID:35273217
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy., PMID:35134084
ACE2 binding is an ancestral and evolvable trait of sarbecoviruses., PMID:35114688
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines., PMID:34619077
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models., PMID:34547465
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design., PMID:34267764
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape., PMID:34261126
SARS-CoV-2 Variants and Vaccines., PMID:34161052
Tackling COVID-19 with neutralizing monoclonal antibodies., PMID:34087172
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein., PMID:33909660
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2., PMID:33761326
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies., PMID:33706364
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2., PMID:33160446
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection., PMID:33139569
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies., PMID:32375025
A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity., PMID:8725098
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
